Collecting tissue samples to study lymph cancer
Official title: Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Run by National Institutes of Health Clinical Center (CC) · NCT01676805 · Data updated 2026-11-12
This study is collecting tissue samples from people with lymphoid cancers to learn more about the disease and help create better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1295 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 2 sites (Bethesda, Maryland and 1 other locations) |
| Status | Recruiting |
| Started | September 21, 2012 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT01676805 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a confirmed diagnosis of lymphoid malignancy or precursor conditions.
✕Probably not a fit
Patients without a diagnosis of lymphoid malignancy or those under 18 years of age may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect various tissue samples from individuals diagnosed with lymphoid cancers or precancerous conditions, including multiple myeloma and different types of lymphoma. Participants will undergo screening through physical exams and medical history assessments, followed by the collection of blood, urine, bone marrow, and tumor tissues. The samples will be analyzed to enhance understanding of cancer biology and to develop new diagnostic and therapeutic approaches. The research is conducted by the National Cancer Institute to support translational trials in lymphoid malignancies.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment options for patients with lymphoid cancers.
How similar studies have gone: Other studies have shown success in using tissue samples to advance understanding and treatment of lymphoid malignancies, making this approach both relevant and promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
* LYMPHOID MALIGNANCIES/DISEASES: The following criteria apply only to patients with a known lymphoid malignancy or precursor disease, as described: INCLUSION CRITERIA: * Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL). * Confirmation of pathological diagnosis is required from the Laboratory of Pathology, NCI. Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care or required testing on an NIH research protocol will be used for diagnosis. * Age \>= 18 years of age * Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document NOTE: Patients enrolling with a LAR must be co-enrolled on another study. EXCLUSION CRITERIA: * Pregnant individuals will not be eligible. * Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, and/or pulmonary dysfunction. * Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator. NON-LYMPHOID MALIGNANCIES/DISEASES: The following criteria apply only to patients without a known lymphoid malignancy or precursor disease, as described: INCLUSION CRITERIA: -Patients without a known lymphoid malignancy or lymphoid precursor diagnosis who have a planned surgical procedure during which blood or normal lymph node(s)/tissue (i.e., those not with pre-determined likelihood of abnormality/ malignancy) may be obtained for research studies as part of this protocol. Patient is appropriate to undergo the surgical procedure planned, and consented for the same, as needed. NOTE: This study will not evaluate eligibility of the patient for surgery. * Age \>= 18 years of age * Must be able and willing to sign informed consent EXCLUSION CRITERIA: * Pregnant individuals will not be eligible. * Other active malignancy. NOTE: Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin as well as any in situ carcinoma are eligible. Patients with a malignancy that has been treated with curative intent and who are without evidence of disease for \>=2 years will also be eligible at the discretion of the investigator. * Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting -
University of the West Indies
Kingston, Jamaica Terminated
Study contacts
- Principal investigator: Christopher J Melani, M.D. — National Cancer Institute (NCI)
- Study coordinator: NCIMO Referral Office
- Email: ncimo_referrals@mail.nih.gov
- Phone: (888) 624-1937
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Collecting biospecimens for cancer research
This study is collecting blood and tumor samples from adults with cancer to help researchers learn more about the disease and improve treatments.
-
Targeted therapy for advanced cancers based on genetic profiling
This study is testing whether targeted treatments based on the genetic makeup of advanced cancers can help patients with conditions like non-Hodgkin lymphoma and multiple myeloma feel better and have more effective options.
-
Using FDA-approved drugs to target specific tumor gene abnormalities in advanced cancer patients
This study is testing if certain FDA-approved drugs can help advanced cancer patients with specific gene changes feel better when standard treatments haven't worked.
-
Study of family connections in blood and lymph cancers
This study looks at families with multiple members diagnosed with blood and lymph cancers to see if genetics and environmental factors play a role in their development.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.